Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Boston Scientific Corporation BSX

Healthcare  —  Medical Devices
43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
S&P 500 Member Cash Flow Champion (3y) Revenue Champion (5y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Boston Scientific Corporation (BSX) Business Profile

Updated before January 2025

Company Overview

Boston Scientific Corporation (BSX) is a global leader in the development, manufacturing, and marketing of medical devices. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company has been at the forefront of innovation in the healthcare industry. Boston Scientific was co-founded by John Abele and Peter Nicholas with the vision of transforming patient care through minimally invasive medical technologies. Over the years, the company has grown into a multinational organization with operations in over 100 countries and a workforce of more than 40,000 employees.

The company’s leadership team is spearheaded by Michael F. Mahoney, who has served as Chairman and Chief Executive Officer since 2012. Under his guidance, Boston Scientific has expanded its product portfolio, entered new markets, and strengthened its position as a leader in the medical device industry. Other key executives include Daniel J. Brennan, Executive Vice President and Chief Financial Officer, and Wendy Carruthers, Executive Vice President of Human Resources.

Core Business Segments

Boston Scientific operates across several core business segments, each focusing on specific areas of healthcare. These segments include:

1. Cardiovascular

Boston Scientific is a pioneer in cardiovascular technologies, offering a wide range of products designed to treat heart and vascular conditions. Key products include:

  • Drug-Eluting Stents (DES): Products like the SYNERGY™ stent are used to treat coronary artery disease.
  • Structural Heart Devices: The WATCHMAN™ Left Atrial Appendage Closure Device is a leading solution for stroke prevention in patients with atrial fibrillation.
  • Interventional Cardiology Tools: Devices such as the AngioJet™ thrombectomy system and Rotablator™ rotational atherectomy system.

2. Rhythm Management

This segment focuses on devices that manage cardiac rhythm disorders. Key offerings include:

  • Implantable Cardioverter Defibrillators (ICDs): Devices like the EMBLEM™ S-ICD System.
  • Pacemakers: Advanced pacemakers such as the INGENIO™ family.
  • Electrophysiology Products: Tools for diagnosing and treating arrhythmias, including the RHYTHMIA HDx™ mapping system.

3. MedSurg

The MedSurg segment encompasses minimally invasive surgical solutions. Key areas include:

  • Endoscopy: Products like the SpyGlass™ DS System for gastrointestinal procedures.
  • Urology and Pelvic Health: Devices such as the Rezūm™ System for benign prostatic hyperplasia (BPH) treatment.

4. Neuromodulation

This segment focuses on devices that treat chronic pain and neurological disorders. Key products include:

  • Spinal Cord Stimulators: The WaveWriter Alpha™ system for pain management.
  • Deep Brain Stimulation (DBS) Systems: Used to treat movement disorders like Parkinson’s disease.

5. Peripheral Interventions

Boston Scientific offers solutions for treating peripheral vascular diseases. Key products include:

  • Drug-Coated Balloons: The Ranger™ DCB for peripheral artery disease.
  • Atherectomy Systems: Devices like the Jetstream™ Atherectomy System.

Business Model

Boston Scientific’s business model revolves around innovation, integration, and customer-centric solutions. The company invests heavily in research and development (R&D), allocating approximately 10-12% of its annual revenue to R&D initiatives. This commitment enables the company to continuously introduce cutting-edge products and expand its portfolio.

Revenue generation is primarily driven by the sale of medical devices, complemented by service contracts and consulting services. Boston Scientific also collaborates with healthcare providers to offer training and support, ensuring the effective use of its products. The company’s global distribution network and strategic partnerships further enhance its market reach.

Strategic Direction

Boston Scientific is focused on achieving sustainable growth through innovation, geographic expansion, and operational excellence. Key strategic priorities include:

  • Product Innovation: The company aims to launch new products and expand its existing portfolio, particularly in high-growth areas like structural heart, electrophysiology, and neuromodulation.
  • Geographic Expansion: Boston Scientific is increasing its presence in emerging markets, including Asia-Pacific and Latin America, to tap into growing healthcare demands.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable practices in manufacturing and operations.
  • Digital Transformation: Leveraging data analytics and artificial intelligence (AI) to enhance product performance and improve patient outcomes.

Competitive Landscape

Boston Scientific operates in a highly competitive industry, facing competition from both large multinational corporations and specialized medical device companies. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of products across various healthcare segments.
  • Abbott Laboratories: Known for its cardiovascular and neuromodulation solutions.
  • Johnson & Johnson (J&J): Competes in areas like interventional cardiology and surgical devices.
  • Stryker Corporation: Focuses on orthopedic and surgical solutions.
  • Edwards Lifesciences: A leader in structural heart devices, particularly transcatheter heart valves.

Risk Factors

Boston Scientific faces several risks that could impact its operations and financial performance. Key risks include:

  • Regulatory Challenges: The medical device industry is heavily regulated, and non-compliance could lead to product recalls or fines.
  • Market Dependence: A significant portion of revenue comes from a few key products, making the company vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on third-party suppliers and global logistics networks exposes the company to potential disruptions.
  • Intellectual Property Risks: Patent disputes and intellectual property challenges could impact product availability.
  • Economic Conditions: Global economic downturns or healthcare budget constraints could affect demand for medical devices.

Recent Developments

Boston Scientific has made significant strides in recent years, including:

  • Product Launches: Introduction of the WaveWriter Alpha™ spinal cord stimulator and the ACURATE neo2™ transcatheter aortic valve system.
  • Acquisitions: Strategic acquisitions like Preventice Solutions, a leader in remote cardiac monitoring, to expand its digital health capabilities.
  • Global Expansion: Opening new facilities and increasing investments in emerging markets.
  • Sustainability Initiatives: Implementation of renewable energy projects and waste reduction programs.

Investment Considerations

Strengths:

  • Strong product portfolio with a focus on innovation.
  • Global presence and diversified revenue streams.
  • Commitment to sustainability and digital transformation.
  • Experienced leadership team.

Risks:

  • Dependence on a few key products for revenue.
  • Regulatory and compliance challenges.
  • Exposure to economic and geopolitical risks.

Conclusion

Boston Scientific Corporation is a leading player in the medical device industry, known for its innovative solutions and commitment to improving patient care. With a robust product portfolio, strategic growth initiatives, and a focus on sustainability, the company is well-positioned for future growth. However, investors should consider the associated risks, including regulatory challenges and market dependence, before making investment decisions.